Shots:
- China’s NMPA has accepted NDA of zurletrectinib (ICP-723) for the treatment of pts (≥12yrs.) with advanced solid tumors having NTRK gene fusions
- In a registrational trial, zurletrectinib demonstrated favorable safety & strong efficacy, with the ability to overcome acquired resistance to the 1st generation TRK inhibitors in mentioned pts
- Zurletrectinib is a next-generation pan-TRK inhibitor that is being evaluated further in a registrational trial for pediatric pts (2-12yrs.)
Ref: Businesswire | Image: InnoCare
Related News:- InnoCare Pharma Reports the IND Clearance of ICP-248 from the US FDA for Hematologic Malignancies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
